FDA advisory panel recommends four peptides for 503A compounding list

The non-binding recommendation could create a regulated US compounding route for BPC-157, KPV, TB-500 and MOTS-c, but it does not approve the substances as drugs or establish their safety or effectiveness.

The FDA’s Pharmacy Compounding Advisory Committee has recommended that BPC-157-, KPV-, TB-500- and MOTS-c-related bulk substances be added to the Section 503A Bulks List after reviewing proposed uses including ulcerative colitis, wound healing, inflammatory conditions, obesity and osteoporosis.

The recommendation concerns compounding eligibility only and remains subject to an FDA decision; none of the peptides has received FDA marketing approval through this process.

Field	Content
Alert Type	Regulatory Recommendation – Compounding
Drug Name	BPC-157, KPV, TB-500 and MOTS-c, including the free-base and acetate forms considered by the committee
Indication	Uses evaluated by the FDA included ulcerative colitis for BPC-157; wound healing and inflammatory conditions for KPV; wound healing for TB-500; and obesity and osteoporosis for MOTS-c.
Therapy Area(s)	Gastroenterology; inflammation and wound care; metabolic disease; bone health
Geography	US (FDA)
What Happened	On 23 July 2026, the FDA’s Pharmacy Compounding Advisory Committee recommended adding four groups of peptide-related bulk substances to the Section 503A Bulks List. The recommendation is advisory and non-binding: the FDA retains responsibility for the final decision, and the vote did not approve the peptides as medicines.
Why It Matters	Inclusion on the Section 503A Bulks List could allow qualifying licensed pharmacists and physicians to use these bulk substances in individually compounded prescriptions, subject to statutory compounding requirements. It would not provide the safety, efficacy, manufacturing or labelling findings associated with FDA approval of a new drug.
Supporting Context	FDA briefing materials had proposed that the free-base and acetate forms of all four peptides should not be included on the Section 503A Bulks List. The committee therefore reached a different recommendation after reviewing the available characterisation, safety, effectiveness and historical-use evidence.
Key Takeaway	The recommendation moves the four peptides closer to possible eligibility for pharmacy compounding but does not make them FDA-approved treatments.
What to Watch	The FDA’s final decision, any formal rulemaking required to amend the Section 503A Bulks List and any conditions or limitations placed on future inclusion.
Primary Source	FDA Pharmacy Compounding Advisory Committee meeting materials
Relevant Date	23 July 2026 — advisory committee recommendation date

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com